Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06667076 · ClinicalTrials.gov registry record · Phase 2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
480
Enrollment target
20
Study locations

NCT06667076: Recruiting Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

NCT06667076 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 480 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06667076, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Primary Outcome

PFS is defined as the time from the date of first dose of any study treatment until the date of objective disease progression or death, whichever occurs first according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 as assessed by the investigator.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Amivantamab
  • DRUG Lazertinib
  • DRUG Chemotherapy: Pemetrexed
  • DRUG Chemotherapy: Carboplatin

Study Locations (20)

California

  • The Oncology Institute of Hope and Innovation - Cerritos
  • City of Hope Corona - Corona
  • City of Hope - Duarte
  • Providence Medical Foundation - Fullerton
  • Oncology Physicians Network Healthcare - Glendale
  • Los Angeles Cancer Network - Glendale
  • Glendale Adventist Medical Center - Glendale
  • Marin Cancer Center - Greenbrae
  • City of Hope Seacliff - Huntington Beach
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • University of California San Diego Health - La Jolla
  • City of Hope Antelope Valley - Lancaster
  • City of Hope Long Beach Elm - Long Beach
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles

Alabama

  • Southern Cancer Center, PC - Daphne
  • Clearview Cancer Institute - Huntsville

Arizona

  • City of Hope Phoenix - Goodyear

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-12-16
Est. Completion 2030-12-26
Phase Phase 2
Janssen Research & Development

593 total trials

What NCT06667076 shows while recruiting

NCT06667076 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Amivantamab is the first listed.

NCT06667076 names 20 study sites across 3 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT06667076 about?

NCT06667076 is a clinical study titled "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of ...

What is the current status of trial NCT06667076?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2024-12-16. Estimated completion is 2030-12-26.

What conditions does trial NCT06667076 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06667076?

The interventions under investigation include: Amivantamab (DRUG), Lazertinib (DRUG), Chemotherapy: Pemetrexed (DRUG), Chemotherapy: Carboplatin (DRUG).

Who is sponsoring clinical trial NCT06667076?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06667076 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06667076's enrollment target sits among peer trials

480 31st of 130 higher than 100 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01954992 · 480 participants · Phase 3

    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  • NCT03023696 · 480 participants · NA

    Can Prophylactic Foraminotomy Prevent C5 Palsy

  • NCT04948060 · 480 participants · NA

    Tribally Engaged Approaches to Lung Screening (TEALS)

  • NCT05053230 · 480 participants · NA

    A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06667076

Source: ClinicalTrials.gov NCT06667076, the US trial registry maintained by the National Library of Medicine. NCT06667076 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.